Dry powder formulations for inhalation o
β
Darragh Murnane; Gary P. Martin; Christopher Marriott
π
Article
π
2009
π
John Wiley and Sons
π
English
β 307 KB
Direct crystallization of active pharmaceutical ingredient (API) particles in the inhalable size range of 1-6 microm may overcome surface energization resulting from micronization. The aerosolization of fluticasone propionate (FP) and salmeterol xinafoate (SX) microcrystals produced by aqueous cryst